Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $51.5 million.

  • Collegium Pharmaceutical's Accumulated Expenses rose 812.61% to $51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.5 million, marking a year-over-year increase of 812.61%. This contributed to the annual value of $72.1 million for FY2024, which is 9196.72% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Accumulated Expenses stood at $51.5 million for Q3 2025, which was up 812.61% from $59.4 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Accumulated Expenses registered a high of $72.1 million during Q4 2024, and its lowest value of $16.9 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $37.6 million (2023), whereas its average is $38.1 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Accumulated Expenses soared by 14309.22% in 2022 and then plummeted by 4050.6% in 2023.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Accumulated Expenses stood at $29.2 million in 2021, then rose by 23.67% to $36.1 million in 2022, then increased by 3.99% to $37.6 million in 2023, then skyrocketed by 91.97% to $72.1 million in 2024, then dropped by 28.64% to $51.5 million in 2025.
  • Its last three reported values are $51.5 million in Q3 2025, $59.4 million for Q2 2025, and $53.7 million during Q1 2025.